Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Konec Inc.
WARNING LETTER
•Konec Inc.

Konec Inc. – FDA Warning Letter

Record Details

The FDA issued a Warning Letter to Konec, Inc. concerning its marketing of unapproved new drugs, specifically Nitroglycerin Tablets (0.3 mg, 0.4 mg, and 0.6 mg). The agency determined these products are "new drugs" under section 201(p) of the Federal Food, Drug, and Cosmetic Act (the Act) because they are not generally recognized as safe and effective for their labeled uses. The primary violations include the introduction or delivery of these unapproved new drugs into interstate commerce without an FDA-approved application, contravening sections 301(d) and 505(a) of the Act. Additionally, the products are deemed misbranded under section 502(f)(1) because their labeling fails to bear adequate directions for use, as they are intended for conditions not amenable to self-diagnosis. The introduction of these misbranded products into interstate commerce further violates sections 301(a) and (d). Konec, Inc. is required to notify the FDA within fifteen working days of receipt of the letter, detailing plans to cease these violative activities. The FDA outlined an enforcement discretion period: it does not intend to initiate enforcement actions for manufacturing continuing up to 90 days post-letter date, or for shipments continuing up to 180 days. This discretion is conditional and will not apply if other violations occur, manufacturing/distribution volume increases, or new health risks emerge. Failure to correct these violations promptly may lead to legal actions like seizure and injunction, and impact federal contract awards.

Company
Konec Inc.
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Deborah M. Autor (Former FDA Deputy Commissioner)
View Company Profile

ID · 97cb0b23-f0b9-490a-8fe7-5e3c5d143d07

Violation Codes10
21 U.S.C. 321(g)(1)(B)21 U.S.C. 321(g)(1)(C)21 U.S.C. 321(p)21 U.S.C. 331(d)21.U.S.C. 355(a)21 U.S.C. 355(b)21 U.S.C. 355(j)21 U.S.C. 352(f)(1)21 CFR 201.11521 U.S.C. 331(a)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Konec Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.